{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.50","upperLimit":"4.87","value":"2.63"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.50","upperLimit":"4.08","value":"2.07"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"}],"units":"Participants"}],"title":"Cycle 2 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"}],"units":"Participants"}],"description":"Crossover C1D1 and crossover C2D1 visits were combined with C1D1 and C2D1 visits, respectively for the analysis of this endpoint.","dispersionType":"Full Range","groups":[{"description":"Participants received AG-120 500 mg, tablet, orally, QD in each 28-day treatment cycle, until occurrence of disease progression, unacceptable toxicity, confirmed pregnancy, death, subject withdrawal, lost to follow-up, or the sponsor ended the study. Participants who experienced disease progression and received placebo were allowed to cross over to receive AG-120 500 mg, tablet, orally, QD in each 28-day treatment cycle.","id":"OG000","title":"Randomization Phase AG-120 Plus Cross Over Phase AG-120"}],"paramType":"MEDIAN","populationDescription":"PK Analysis Population consisted of all participants who were enrolled and received at least one dose of study medication (AG-120) with sufficient plasma sample data to assess PK parameters. Number analyzed is the number of participants with data available for analyses at the specified time point.","reportingStatus":"POSTED","timeFrame":"Post-dose Cycle 1 Day 1 and Cycle 2 Day 1 (each cycle = 28 days)","title":"Time to Reach Maximal Plasma Concentration (Tmax) of AG-120","type":"SECONDARY","unitOfMeasure":"hours (h)"}